Under Section 312.120, sponsors submit
foreign clinical studies not conducted under an Investigational New
Drug as support for an IND or application for marketing approval
for a drug or biological product. The studies must be conducted in
accordance with Good Clinical Practice, including review and
approval by an independent ethics committee.
The burden estimates
preapproved by the Office of Management and Budget in the April 28,
2008 final rule have been updated by FDA's Economics Staff to
reflect current burdens.
$0
No
Yes
No
No
No
Uncollected
ILa Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.